Time-of-Day Effects of Green Tea Extract on Postprandial Glycemia and Insulinemia in Healthy Adults: Insights from a Randomized Controlled Cross-Over Trial
Posted inClinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Time-of-Day Effects of Green Tea Extract on Postprandial Glycemia and Insulinemia in Healthy Adults: Insights from a Randomized Controlled Cross-Over Trial

Green tea extract reduces morning postprandial insulin peaks but does not alter glucose levels, with notable time-dependent effects linked to circadian rhythms influencing insulin sensitivity in healthy adults.
Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial
Posted inCardiology Clinical Updates news Public Health Respiratory Specialties

Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial

This review synthesizes trial evidence showing that nicotine-containing e-cigarettes modestly improve lipid profiles but cause no significant changes in lung function or other cardiovascular markers compared to cigarette substitutes in smokers reducing cigarette use.
Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept
Posted inAllergy & Immunology Clinical Updates Nephrology Specialties

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-modifying therapeutic options.